Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Primary Sclerosing Cholangitis Market trend, outlook 2025

Author: Ravikiran Bhosale
by Ravikiran Bhosale
Posted: Jul 20, 2018

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Get PDF Research Brochure for more Professional and Technical Insights:

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.

Key features of the study:

  • This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same
  • It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Ask for Customization :

Detailed Segmentation:

  • Global Primary Sclerosing Cholangitis Market, By Drug:
    • BTT1023
    • GS-9674
    • NGM282
    • OCA
    • Cenicriviroc
    • LUM001
    • DUR928
    • norUDCA
    • HTD1801
    • IDN-7314
    • STP705
  • Global Primary Sclerosing Cholangitis Market, By Region:
    • North America
      • Regional Overview
    • Latin America
      • Regional Overview
    • Europe
      • Regional Overview
    • Asia Pacific
      • Regional Overview
    • Middle East
      • Regional Overview
    • Africa
      • Regional Overview
  • Company Profiles
    • Acorda Therapeutics, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Gilead Sciences, Inc.
    • NGM Biopharmaceuticals, Inc.
    • Intercept Pharmaceuticals, Inc.
    • Dr. Falk Pharma GmbH
    • Allergan Plc.
    • Shire Plc.
    • Durect Corporation
    • Conatus Pharmaceuticals, Inc.
    • Sirnaomics, Inc.
    • Shenzhen HighTide Biopharmaceuticals Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702


About the Author

Submitting intelligent market insights of the market situations for healthcare services

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Author: Ravikiran Bhosale

Ravikiran Bhosale

Member since: May 31, 2018
Published articles: 316

Related Articles